Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

In vivo functional screening via CRISPR-Cas9 to systematically identify cardiomyocyte receptors as targets for the innovative therapies for myocardial infarction and heart failure

Descripción del proyecto

El papel de los receptores de los cardiomiocitos en el infarto de miocardio

El equipo del proyecto financiado con fondos europeos R-FunSel trabaja para identificar nuevas dianas terapéuticas para el infarto de miocardio (IM), la principal causa de insuficiencia cardíaca. Los investigadores están empleando la tecnología de edición del genoma CRISPR/Cas9 para llevar a cabo un cribado sistemático «in vivo» de los receptores de los cardiomiocitos. Para ello, emplearán un modelo murino del IM e identificarán genes necesarios para la supervivencia de los cardiomiocitos, genes cardioprotectores y genes que codifican para factores dañinos. El método propuesto proporciona una forma imparcial de obtener información sobre los mecanismos del IM, lo que contribuye a la aplicación de la investigación fundamental en el descubrimiento de nuevas dianas terapéuticas.

Objetivo

Myocardial Infarction (MI) is the leading cause of heart failure, which represents a major medical, social and economic burden worldwide. There is a desperate need for new therapies for these conditions. Here we propose a new approach for the in vivo, unbiased and systematic identification of receptors involved in MI, which might become targets for innovative therapeutics. The method we developed, named Reverse Functional Selection (R-FunSel) takes advantage of the CRISPR/Cas9 genome editing technology and is based on the intracardiac screening of a library of single-guide (sg) RNAs in Cas9 transgenic mice upon gene delivery using the highly cardiotropic adeno-associated virus serotype 9 (AAV9). First, we will construct an arrayed library of sgRNAs, individually cloned into AAV9 vectors, driving CRISPR/Cas9 towards each of the receptor genes expressed by cardiomyocytes. Second, we will package pools of this library and transduce the mouse heart, at a multiplicity by which each vector enters a different cell. Then, MI will be applied as a selective stimulus and, after a few weeks, vector inserts will be recovered from the viable tissue and their frequency measured by Next Generation Sequencing. R-FunSel is based on Darwinian selection of cardiomyocyte survival, thus sgRNAs that will be lost are likely to target cardioprotective genes while those that are enriched code for detrimental factors. The choice to develop R-FunSel for the systematic screening of cardiomyocyte receptors will allow identification of novel druggable targets for the development of therapeutics, either in the form of molecules activating the protective receptors or inhibiting them or their ligands. R-FunSel is based on solid technologies that support the feasibility and power of the in vivo screening approach. Compared to biochemical or phenotypic studies, screening in vivo directly for function is a novel strategy to move basic research into translational medicine at a quick pace.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Régimen de financiación

MSCA-IF-EF-ST - Standard EF

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) H2020-MSCA-IF-2018

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

KING'S COLLEGE LONDON
Aportación neta de la UEn
€ 212 933,76
Dirección
STRAND
WC2R 2LS London
Reino Unido
Región
London Inner London — West Westminster
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 212 933,76